摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3-methyl-urea | 839712-15-1

中文名称
——
中文别名
——
英文名称
trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3-methyl-urea
英文别名
Desmethyl cariprazine;1-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-3-methylurea
trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3-methyl-urea化学式
CAS
839712-15-1
化学式
C20H30Cl2N4O
mdl
——
分子量
413.39
InChiKey
WMQLLTKSISGWHQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    27
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.65
  • 拓扑面积:
    47.6
  • 氢给体数:
    2
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3-methyl-urea甲烷磺酸溶剂黄146 作用下, 以 四氢呋喃甲苯 为溶剂, 反应 20.0h, 生成 N'-[(1r,4r)-4-{2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl}cyclohexyl]-N-methyl-N-(propoxymethyl)urea
    参考文献:
    名称:
    DOPAMINE D3/D2 RECEPTOR MODULATING COMPOUNDS
    摘要:
    本公开提供式(I)的化合物: 其中R1具有说明书中所定义的任意值,以及药学上可接受的盐,它们作为治疗包括精神分裂症在内的疾病和病症的药物有效。此外,还提供了包含式(I)化合物的药物组合物。 (注:式(I)的结构图在实际文本中应位于相应位置,此处为文字描述。)
    公开号:
    EP4400495A1
点击查看最新优质反应信息

文献信息

  • [EN] (THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE (THIO) CARBAMOYL-CYCLOHEXANE UTILISES EN TANT QU'ANTAGONISTES DES RECEPTEURS D3/D2
    申请人:RICHTER GEDEON VEGYESZET
    公开号:WO2005012266A1
    公开(公告)日:2005-02-10
    The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): wherein R1 and R2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R1 and R2 may form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.
    本发明涉及新的D3和D2多巴胺受体亚型偏好配体,其化学式为(I):其中R1和R2分别代表氢,烷基,芳基,环烷基,芳香酰基的取代基,或者R1和R2可以与相邻的氮原子形成杂环;X代表氧或原子;n为1至2的整数,以及它们的几何异构体和/或立体异构体和/或对映异构体和/或盐和/或合物和/或溶剂化物,以及制备它们的方法,包含它们的制药组合物以及在需要调节多巴胺受体的情况下用于治疗和/或预防的用途。
  • (THIO) Carbamoyl-Cyclohexane Derivatives as D3/D2 Receptor Antagonists
    申请人:Csongor Eva Againe
    公开号:US20100240640A1
    公开(公告)日:2010-09-23
    The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): wherein R 1 and R 2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R 1 and R 2 may form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.
    本发明涉及一种新的D3和D2多巴胺受体亚型偏好配体,其化学式为(I):其中R1和R2分别表示从氢,烷基,芳基,环烷基,芳酰基中选择的取代基,或者R1和R2可以与相邻的氮原子形成杂环;X表示氧或原子;n是1到2的整数,以及它们的几何异构体和/或立体异构体和/或对映异构体和/或盐和/或合物和/或溶剂化物,以及制备它们的过程,含有它们的制药组合物以及它们在治疗和/或预防需要调节多巴胺受体的疾病中的应用。
  • (THIO) Carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
    申请人:Csongor Againe Eva
    公开号:US20060229297A1
    公开(公告)日:2006-10-12
    The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): wherein R 1 and R 2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R 1 and R 2 may form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.
    本发明涉及公式(I)的新的D3和D2多巴胺受体亚型偏好配体,其中R1和R2分别表示从氢,烷基,芳基,环烷基,芳香基或R1和R2可以与相邻的氮原子形成杂环环;X表示氧原子或原子;n为1到2的整数,以及它们的几何异构体和/或立体异构体和/或对映异构体和/或盐和/或合物和/或溶剂化物,以及制备它们的过程,含有它们的制药组合物以及它们在调节多巴胺受体所需的治疗和/或预防疾病中的使用。
  • (THIO)CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS
    申请人:Richter Gedeon Nyrt.
    公开号:EP1663996B1
    公开(公告)日:2012-06-20
  • US7737142B2
    申请人:——
    公开号:US7737142B2
    公开(公告)日:2010-06-15
查看更多